KALA BIO, Inc. (NASDAQ:KALA – Get Free Report) CEO Mark T. Iwicki sold 15,168 shares of the business’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total transaction of $72,048.00. Following the sale, the chief executive officer now owns 263,755 shares of the company’s stock, valued at $1,252,836.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
KALA BIO Trading Up 9.9 %
Shares of KALA stock opened at $7.09 on Friday. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $16.11. The firm has a fifty day moving average price of $6.39 and a 200-day moving average price of $7.02. The company has a debt-to-equity ratio of 4.92, a current ratio of 4.22 and a quick ratio of 4.22. The company has a market cap of $19.99 million, a price-to-earnings ratio of -0.47 and a beta of -1.97.
KALA BIO (NASDAQ:KALA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($4.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.89) by ($1.31). As a group, equities analysts predict that KALA BIO, Inc. will post -14.49 earnings per share for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
A number of equities research analysts have weighed in on KALA shares. HC Wainwright decreased their target price on shares of KALA BIO from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 17th. Oppenheimer reissued an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Monday, April 1st.
View Our Latest Stock Analysis on KALA
KALA BIO Company Profile
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Read More
- Five stocks we like better than KALA BIO
- Russell 2000 Index, How Investors Use it For Profitable Trading
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Best Stocks Under $10.00
- MarketBeat Week in Review – 6/24 – 6/28
- How to Invest in Insurance Companies: A Guide
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.